---
layout: post
title: "抄底的笑了！港A医药股集体大反弹！“春日升机”将现？券商建议关注四条主线(附股)"
date: 2022-02-25 14:26:40 +0800
categories: emnews
tags: 东财滚动新闻
---
> 抄底的笑了！港A医药股集体大反弹！“春日升机”将现？券商建议关注四条主线(附股)。

<p>医药股从去年下半开始持续调整，板块指数最大回撤近30%。不过今年春节后，医药股频频反弹，今日港A生物医药板块再度大涨。</p><p>截至发稿，港股方面，<span id="Info.116.09995"><a href="http://quote.eastmoney.com/unify/r/116.09995" class="keytip" data-code="116,09995">荣昌生物-B</a></span>大涨近13%，<span id="Info.116.06127"><a href="http://quote.eastmoney.com/unify/r/116.06127" class="keytip" data-code="116,06127">昭衍新药</a></span>涨超10%，<span id="Info.116.09688"><a href="http://quote.eastmoney.com/unify/r/116.09688" class="keytip" data-code="116,09688">再鼎医药-SB</a></span>涨超9%，<span id="Info.116.01801"><a href="http://quote.eastmoney.com/unify/r/116.01801" class="keytip" data-code="116,01801">信达生物</a></span>涨超8%；A股通方面，<span id="stock_1.688298"><a href="http://quote.eastmoney.com/unify/r/1.688298" class="keytip" data-code="1,688298">东方生物</a></span><span id="quote_1.688298"></span>涨超13%，<span web="1" href="http://quote.eastmoney.com/unify/r/116.06127" class="em_stock_key_common" data-code="116,06127">昭衍新药</span>涨近9%，<span id="stock_1.600763"><a href="http://quote.eastmoney.com/unify/r/1.600763" class="keytip" data-code="1,600763">通策医疗</a></span><span id="quote_1.600763"></span>涨超8%，<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>涨超6%，<span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>涨近5%。<a href="https://hk.eastmoney.com/a/202202162277791536.html"><strong>(海外投资者如何投资A股通？)</strong></a></p><p>A股细分板块中，CXO概念板块指数更是飙涨近6%，近两周该指数已较低点上涨逾15%；医疗保健板块指数亦大涨逾4%，新冠药概念、新冠检测、免疫治疗等板块均拉升超3%。</p><p>今日，<strong>在国新办新闻发布会上，科技部部长王志刚表示，面向人民生命健康，坚持人民至上、生命至上，把增强人民群众的健康福祉作为科技研发的重要导向。</strong>支撑疫情防控，检测手段更迅速更便捷更精准，药物研发取得突破性进展，疫苗研发积极适应疫情和病毒新的变化，在实践中不断验证其有效性和安全性。加快药物和<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>研发，通过实施新药创制重大专项，<strong>我国获批I类新药从2008年之前的5个达到现在的75个新品药，以正电子磁共振扫描系统(PET/MR)为代表的一批国产高端<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1041" class="em_stock_key_common" data-code="90,BK1041">医疗器械</span>投入使用。</strong></p><p>此外，<strong><span web="1" href="http://quote.eastmoney.com/unify/r/116.01801" class="em_stock_key_common" data-code="116,01801">信达生物</span>今日宣布其自主研发的抗白细胞分化抗原73(CD73)单克隆抗体(研发代号：IBI325)在治疗晚期实体瘤的I期临床试验中完成首例患者给药。</strong></p><p>该研究为评估IBI325治疗晚期恶性肿瘤的安全性、耐受性和有效性的开放、多中心1a/1b期研究，主要目的是评价IBI325单药或联合信迪利单抗，在治疗晚期实体瘤受试者中的安全性、耐受性、药代动力学和初步疗效，并为后续研究提供推荐剂量。</p><p><strong><span id="stock_1.601375"><a href="http://quote.eastmoney.com/unify/r/1.601375" class="keytip" data-code="1,601375">中原证券</a></span><span id="quote_1.601375"></span></strong>分析认为，“疫苗+新冠药物”仍然是未来抗疫的主要手段，<strong>建议持续关注疫苗和新冠药物领域的投资机会</strong>，重点公司包括<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>(300122)、<span id="stock_0.300142"><a href="http://quote.eastmoney.com/unify/r/0.300142" class="keytip" data-code="0,300142">沃森生物</a></span><span id="quote_0.300142"></span>(300142)、康希诺(688185)、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>(300601)、<span id="stock_1.603392"><a href="http://quote.eastmoney.com/unify/r/1.603392" class="keytip" data-code="1,603392">万泰生物</a></span><span id="quote_1.603392"></span>(603392)、<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>(688180)。</strong></p><p>随着新冠肺炎药物的获批上市，保障原料供应与产能是必备条件，新冠药物原料供应相关企业也值得重点关注，如<strong><span id="stock_1.603811"><a href="http://quote.eastmoney.com/unify/r/1.603811" class="keytip" data-code="1,603811">诚意药业</a></span><span id="quote_1.603811"></span>(603811)，<span id="stock_0.002001"><a href="http://quote.eastmoney.com/unify/r/0.002001" class="keytip" data-code="0,002001">新和成</a></span><span id="quote_0.002001"></span>(002001)、<span id="stock_0.300584"><a href="http://quote.eastmoney.com/unify/r/0.300584" class="keytip" data-code="0,300584">海辰药业</a></span><span id="quote_0.300584"></span>(300584)、<span id="stock_0.300497"><a href="http://quote.eastmoney.com/unify/r/0.300497" class="keytip" data-code="0,300497">富祥药业</a></span><span id="quote_0.300497"></span>(300497)。</strong></p><p>创新药发展步入突破性创新阶段，CXO估值调整较多，随着年报的披露，可以继续关注CXO的投资机会，建议重点关注<strong><span web="1" href="http://quote.eastmoney.com/unify/r/116.06127" class="em_stock_key_common" data-code="116,06127">昭衍新药</span>(603127)</strong>。</p><p>CRO俗称医药研发外包。更上一层的概念为CXO(医药外包)，包括CRO、CMO/CDMO、CSO概念，分别服务于医药研发、生产、销售三大环节。</p><p><strong><span id="stock_1.601555"><a href="http://quote.eastmoney.com/unify/r/1.601555" class="keytip" data-code="1,601555">东吴证券</a></span><span id="quote_1.601555"></span>认为</strong>，2022年国内主流CXO公司平均市盈率为41倍，与国外CXO公司相比，估值已经大幅消化。回顾2021年全球及中国药企研发投入、新药管线数量、医疗健康产业融资额与融资数，<strong>A股CXO需求不减，仍具备充足动能。国内CXO公司2021年<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>预告也展现出CXO业绩能见度并未改变，具备配置价值</strong>。</p><p><strong>平安<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>维持医药生物行业“强于大市”评级，建议关注以下四条主线：</strong></p><p><strong>主线一：创<span id="stock_0.300832"><a href="http://quote.eastmoney.com/unify/r/0.300832" class="keytip" data-code="0,300832">新产业</a></span><span id="quote_0.300832"></span>链</strong>，包括创新药(械)和CXO.CDE新政加速国内创新“新生态”进化，行业面临“再分化”，关注具备临床导向创新能力及license-out能力的公司，</p><p>建议关注：<strong><span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>、<span id="Info.116.06160"><a href="http://quote.eastmoney.com/unify/r/116.06160" class="keytip" data-code="116,06160">百济神州</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.01801" class="em_stock_key_common" data-code="116,01801">信达生物</span>、<span id="stock_106.GLW"><a href="http://quote.eastmoney.com/unify/r/106.GLW" class="keytip" data-code="106,GLW">康宁</a></span><span id="quote_106.GLW"></span>杰瑞、<span id="stock_1.688321"><a href="http://quote.eastmoney.com/unify/r/1.688321" class="keytip" data-code="1,688321">微芯生物</a></span><span id="quote_1.688321"></span></strong>。CXO方面，维持高景气度，结合估值以及政策、资金因素，平安<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>更倾向于CDMO和大分子CXO赛道，建议关注：<strong><span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span></strong>。</p><p><strong>主线二：产品出海。</strong>海外市场是巨大的增量市场，制剂出口有较高门槛，<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1041" class="em_stock_key_common" data-code="90,BK1041">医疗器械</span>出海也成为行业新的增长驱动力。</p><p>建议关注：<strong><span id="stock_1.603707"><a href="http://quote.eastmoney.com/unify/r/1.603707" class="keytip" data-code="1,603707">健友股份</a></span><span id="quote_1.603707"></span>、<span id="stock_0.300630"><a href="http://quote.eastmoney.com/unify/r/0.300630" class="keytip" data-code="0,300630">普利制药</a></span><span id="quote_0.300630"></span>、<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span></strong>等。</p><p><strong>主线三：</strong><strong>消费型医疗。</strong>随着人均可支配收入增长，消费型医疗需求不断提升。同时，消费型医疗均为自费产品，有自主定价权，免疫控费政策。</p><p>建议关注：<strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.600763" class="em_stock_key_common" data-code="1,600763">通策医疗</span>、<span id="stock_0.300015"><a href="http://quote.eastmoney.com/unify/r/0.300015" class="keytip" data-code="0,300015">爱尔眼科</a></span><span id="quote_0.300015"></span>、<span id="stock_0.300653"><a href="http://quote.eastmoney.com/unify/r/0.300653" class="keytip" data-code="0,300653">正海生物</a></span><span id="quote_0.300653"></span></strong>等。</p><p><strong>主线四：<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>板块此前长期处于调整阶段，整体估值较低。</strong>板块中业绩增长稳健的企业性价比高，布局优势凸显。且<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>产品出口少，内循环属性明显。一些<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>产品更加偏向于保健品，消费属性更强，可对标部分食品企业。</p><p>在此前提下，平安<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>认为，调整充分、估值较低的标的值得重点关注。这其中，免疫医保控费政策的OTC药品占比更大、产品有较好的提价空间且中药注射剂占比更小的企业有更大的弹性，建议关注：<strong><span id="stock_1.600285"><a href="http://quote.eastmoney.com/unify/r/1.600285" class="keytip" data-code="1,600285">羚锐制药</a></span><span id="quote_1.600285"></span>、<span id="stock_1.600422"><a href="http://quote.eastmoney.com/unify/r/1.600422" class="keytip" data-code="1,600422">昆药集团</a></span><span id="quote_1.600422"></span></strong>等。</p><p>在上述几条主线外，还存在一些其他高景气、高壁垒的赛道：包括特色原料药与核医学等。建议关注：<strong><span id="stock_1.603520"><a href="http://quote.eastmoney.com/unify/r/1.603520" class="keytip" data-code="1,603520">司太立</a></span><span id="quote_1.603520"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300497" class="em_stock_key_common" data-code="0,300497">富祥药业</span>、<span id="stock_0.300702"><a href="http://quote.eastmoney.com/unify/r/0.300702" class="keytip" data-code="0,300702">天宇股份</a></span><span id="quote_0.300702"></span>、<span id="stock_0.002675"><a href="http://quote.eastmoney.com/unify/r/0.002675" class="keytip" data-code="0,002675">东诚药业</a></span><span id="quote_0.002675"></span>、<span id="Info.116.00512"><a href="http://quote.eastmoney.com/unify/r/116.00512" class="keytip" data-code="116,00512">远大医药</a></span></strong>。</p><center><img src="https://dfscdn.dfcfw.com/download/D24977528720720855214_w878h1760.jpg" emheight="1163" orginial_src="https://dfscdn.dfcfw.com/download/D24977528720720855214_w878h1760_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" width="580" /></center><center><img src="https://dfscdn.dfcfw.com/download/D25216549303965067629_w878h1760.jpg" emheight="1163" orginial_src="https://dfscdn.dfcfw.com/download/D25216549303965067629_w878h1760_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" width="580" /></center><p><strong>相关阅读：</strong></p><p><strong><a href="https://finance.eastmoney.com/a/202202252289327238.html">抄底的笑了！创业板半日涨超2% 医药股王者归来 “春日升机”将现？</a><br /></strong></p><p><strong><a href="https://stock.eastmoney.com/a/202202252289188775.html">八大券商主题策略：关注四条主线！调整充分、估值较低的医药标的名单来了</a><br /></strong></p><p><strong><a href="https://stock.eastmoney.com/a/202202252289217143.html">医药股集体大反弹！通策医疗等多股涨停 回调后性价比凸显</a><br /></strong></p><p><strong><a href="https://finance.eastmoney.com/a/202202252289297596.html">医药股大反弹！葛兰开始“回血” 年报披露进入高峰 这些A股“好学生”受青睐</a><br /></strong></p><p class="em_media">（文章来源：哈富证券）</p>

<http://hk.eastmoney.com/news/11382,202202252289457082.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)